Acadia Reports New Positive Data For Phase 2 Remlifanserin Study In Alzheimer's Psychosis

Acadia Pharmaceuticals (ACAD) reported positive Phase 2 trial results for Remlifanserin in treating Alzheimer's disease psychosis. The 60 mg dose showed improvement over placebo in key measures. ACAD stock closed at $18.32, down 1.87%.

Original reporting
Published Nov 18, 2026, 10:08 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 18, 2026, 10:11 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Acadia Reports New Positive Data For Phase 2 Remlifanserin Study In Alzheimer's Psychosis — source image
Decision brief

The 30-second read

$ACADBullishMed
01

Why it matters

The trial results provide the first substantive efficacy readout for remlifanserin, a 5HT2A inverse agonist targeting Alzheimer's psychosis.

02

Market read

First‑report Phase 2 data for a neuro‑psychiatric drug; could influence ACAD stock and related biotech peers.

03

What to watch

Potential safety signals or regulatory hurdles could temper enthusiasm despite the efficacy signals.

Relevance 8/10Novelty 8/10Timing: today

Background

Acadia presented the data at the 2026 Clinical Trials on Alzheimer's Disease conference in Boston.

Company-level read

Ticker impact

$ACADBullishHigh confidence
Context

Acadia Pharmaceuticals released new Phase 2 RADIANT trial data for remlifanserin showing statistically significant improvement on secondary endpoints.

Expected impact

potential upside as investors price in the encouraging trial results

Evidence & confidence

Phase 2 data is a material catalyst for a biotech; the 60 mg dose showed improvement over placebo on CGI‑S‑ADP and NPI scores, which often precedes a share price bounce.

Market effects

May boost confidence in the Alzheimer's psychosis therapeutic space and could lift peer biotech stocks developing similar agents.

Limited to U.S. biotech sector; no broader regional effect.

Relevant to global investors tracking neuro‑psychiatric drug pipelines.

Counterpoint

The data, while positive, still reflects a Phase 2 study; investors may wait for Phase 3 confirmation before committing.

Key entities

  • Acadia Pharmaceuticals Inc.

    Developer of remlifanserin, listed on NASDAQ.

Related articles

$ACADMed

Acadia presents additional data on Alzheimer’s psychosis drug

Acadia Pharmaceuticals (NASDAQ:ACAD) presented additional data from its Phase 2 RADIANT trial of remlifanserin for Alzheimer’s disease psychosis, showing consistent efficacy signals at the 60 mg dose. The drug previously missed its primary endpoint but achieved nominal significance on key secondary endpoints. The company continues Phase 3 trials and is also investigating the drug for Lewy body dementia psychosis.